Following Lilly, Roche has also received approval for its RET targeted anticancer therapy. The entrance of two drugs in a similar period is expected to spark new competition in the RET-targeted therapy market.

On the 29th, Roche received marketing authorization for ‘Gavreto (pralsetinib) from the Ministry of Food and Drug Safety. Its first indications are for non-small cell lung cancer and thyroid cancer.

More specifically, Gavreto was approved for the treatment of adult patients with RET fusion-positive locally advanced or metastatic NSCLC, and adult patients with RET-mutated locally advanced or metastatic medullary thyroid cancer that require systemic therapy.

Gavreto i